Results 181 to 190 of about 18,037 (235)

Mineralocorticoid receptor antagonist treatment in patients with renal insufficiency and the associated risk of hyperkalemia and death. [PDF]

J Hypertens
Hedlund Møller S, Haagensen Kofod D, Schou M, Torp-Pedersen C, Gislason G, Carlson N, Lindhardt M.   +6 more
europepmc   +1 more source

Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial. [PDF]

Kidney Dis (Basel)
Cherney DZI, Frederich R, Pratley RE, Cosentino F, Dagogo-Jack S, Pong A, Gantz I, Cater NB, Mancuso JP, Masiukiewicz U, Cannon CP.   +10 more
europepmc   +1 more source

A Randomized trial assessing Efficacy and safety of Mineralocorticoid receptor Antagonist therapy compared to Standard antihypertensive Therapy in hypErtension with low Renin (REMASTER): rationale and study design. [PDF]

J Hum Hypertens
Shah SS, Gwini SM, Stowasser M, Reid CM, Young MJ, Fuller PJ, Yang J.   +6 more
europepmc   +1 more source

Protective Effects of Selective Mineralocorticoid Receptor Antagonist in Alport Syndrome on Top of Renin-Angiotensin-System/ Sodium-Glucose Transporter 2 Blockade. [PDF]

Kidney Int Rep
Song ZR, Li Y, Zhang H, Zhou XJ.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid receptor antagonists

2023
Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines, while recommending MRAs, do not make a clear recommendation as to which MRAs should be used, how doses should be titrated, or ...
Bertram Pitt, João Pedro Ferreira, Faiez Zannad   +2 more
openaire   +1 more source